These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24115384)

  • 1. Assessing patients with hepatocellular carcinoma meeting the Milan criteria: Is liver 3 tesla MR with gadoxetic acid necessary in addition to liver CT?
    Cha DI; Lee MW; Kim YK; Kim SH; Park HJ; Rhim H; Lim HK
    J Magn Reson Imaging; 2014 Apr; 39(4):842-52. PubMed ID: 24115384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
    Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
    Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.
    Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Muhi A; Araki T
    Radiology; 2010 Jul; 256(1):151-8. PubMed ID: 20574092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
    Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
    Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
    Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
    Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
    Park MJ; Kim YK; Lee MH; Lee JH
    Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.
    Kim SH; Kim SH; Lee J; Kim MJ; Jeon YH; Park Y; Choi D; Lee WJ; Lim HK
    AJR Am J Roentgenol; 2009 Jun; 192(6):1675-81. PubMed ID: 19457834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
    Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
    J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detectability of hepatocellular carcinoma on gadoxetic acid-enhanced MRI at 3 T in patients with severe liver dysfunction: clinical impact of dual-source parallel radiofrequency excitation.
    Nishie A; Kakihara D; Asayama Y; Ushijima Y; Takayama Y; Fujita N; Shimamoto D; Shirabe K; Hida T; Honda H
    Clin Radiol; 2015 Mar; 70(3):254-61. PubMed ID: 25522901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of small (≤2 cm) hepatocellular carcinomas from small benign nodules in cirrhotic liver on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance images.
    Kwon HJ; Byun JH; Kim JY; Hong GS; Won HJ; Shin YM; Kim PN
    Abdom Imaging; 2015 Jan; 40(1):64-75. PubMed ID: 24997560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.
    Kim JE; Kim SH; Lee SJ; Rhim H
    AJR Am J Roentgenol; 2011 Jun; 196(6):W758-65. PubMed ID: 21606265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
    Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
    Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.
    Ahn SS; Kim MJ; Lim JS; Hong HS; Chung YE; Choi JY
    Radiology; 2010 May; 255(2):459-66. PubMed ID: 20413759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.